| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (NCT03064854) | Novartis Pharmaceuticals | 2017-05-24 |
| Microbiota and the Lung Cancer (NCT03068663) | Centre Jean Perrin | 2017-05-23 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (NCT03125200) | ADC Therapeutics S.A. | 2017-05-18 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours (NCT03101839) | AstraZeneca | 2017-05-15 |
| Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC (NCT03141359) | Wake Forest University Health Sciences | 2017-05-12 |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (NCT02314481) | University College, London | 2017-05-12 |
| Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer (NCT02898116) | Ludwig Institute for Cancer Research | 2017-05-10 |
| Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717) | Dana-Farber Cancer Institute | 2017-05-09 |
| Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect (NCT03825510) | Crozer-Keystone Health System | 2017-04-28 |
| Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC) (NCT03198117) | Qidong Gaitianli Medicines Co., Ltd | 2017-04-25 |
| Clinical Trial in Chinese Healthy Volunteers of GB222 (NCT04175158) | Genor Biopharma Co., Ltd. | 2017-04-24 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study (NCT03875092) | Merck Sharp & Dohme LLC | 2017-04-21 |
| A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) (NCT02927301) | Genentech, Inc. | 2017-04-20 |
| Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala (NCT03209128) | Centre Francois Baclesse, Luxembourg | 2017-04-20 |
| Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients (NCT03081689) | Spanish Lung Cancer Group | 2017-04-15 |
| Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer (NCT03091491) | National Cancer Centre, Singapore | 2017-04-07 |
| International Lung Screen Trial (ILST) (NCT02871856) | The University of Queensland | 2017-04-05 |
| Detection of Circulating Biomarkers of Immunogenic Cell Death (NCT02921854) | Maastricht Radiation Oncology | 2017-04-04 |
| β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC (NCT03123484) | China Medical University, China | 2017-04-01 |
| A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan (NCT03273790) | Bristol-Myers Squibb | 2017-04-01 |
| Endostar First-line Treatment of Advanced NSCLC (NCT03123445) | China Medical University, China | 2017-04-01 |
| An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (NCT03001882) | Bristol-Myers Squibb | 2017-03-29 |
| Phase II Trial of Continuation Therapy in Advanced NSCLC (NCT03083808) | Greg Durm, MD | 2017-03-20 |
| Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors (NCT02706626) | Criterium, Inc. | 2017-03-09 |
| Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (NCT02879760) | Turnstone Biologics, Corp. | 2017-03-08 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (NCT02998528) | Bristol-Myers Squibb | 2017-03-04 |
| Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC (NCT02908750) | AstraZeneca | 2017-03-02 |
| Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients (NCT02758314) | Instituto Nacional de Cancerologia de Mexico | 2017-03-01 |
| To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer (NCT03195569) | Qilu Pharmaceutical Co., Ltd. | 2017-03-01 |
| Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor (NCT03093688) | Shanghai Public Health Clinical Center | 2017-03-01 |
| The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients (NCT03228368) | First Affiliated Hospital of Zhejiang University | 2017-03-01 |
| Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC (NCT03130764) | Columbia University | 2017-03-01 |
| Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC (NCT02929290) | Betta Pharmaceuticals Co., Ltd. | 2017-03-01 |
| Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy (NCT03017885) | Boehringer Ingelheim | 2017-02-28 |
| Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (NCT03074864) | Guangdong Provincial People's Hospital | 2017-02-27 |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (NCT02974725) | Novartis Pharmaceuticals | 2017-02-24 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC (NCT03614065) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2017-02-21 |
| Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study (NCT02803333) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) (NCT05221372) | Erasmus Medical Center | 2017-02-02 |
| AVID100 in Advanced Epithelial Carcinomas (NCT03094169) | Formation Biologics | 2017-02-01 |
| Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer (NCT03724500) | Chang Gung Memorial Hospital | 2017-02-01 |
| Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC (NCT04530708) | Swedish Lung Cancer Study Group | 2017-02-01 |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (NCT02998567) | Royal Marsden NHS Foundation Trust | 2017-01-26 |
| 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer (NCT03065764) | Amsterdam UMC, location VUmc | 2017-01-20 |
| A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies (NCT03056300) | Ethicon, Inc. | 2017-01-11 |
| PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer (NCT03099577) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-01-02 |
| Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer (NCT07099105) | Korea University Guro Hospital | 2017-01-01 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| Effect of Preoperative Oral Carbohydrate Administration in Thoracic Surgery Patients (NCT05005091) | Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital | 2017-01-01 |
| Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02944396) | AbbVie | 2016-12-23 |
| A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy (NCT03130192) | Chung Shan Medical University | 2016-12-22 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (NCT02183883) | University College, London | 2016-12-16 |
| Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (NCT03086733) | University Health Network, Toronto | 2016-12-05 |
| Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (NCT06207292) | Radiotherapy Oncology Centre "Santa Maria" Hospital | 2016-12-01 |
| Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC (NCT04710459) | Mohamed Abdel Bary Ahmed Ibrahim | 2016-12-01 |
| An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (NCT03129256) | Changzhou Cancer Hospital of Soochow University | 2016-12-01 |
| Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC (NCT03374280) | Guangzhou Medical University | 2016-12-01 |
| Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury (NCT03632369) | Thunder Bay Regional Health Research Institute | 2016-12-01 |
| Food Reward in Cachexia Induced by Acute or Chronic Disease (NCT02798003) | Maastricht University Medical Center | 2016-12-01 |
| Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) (NCT03060343) | Yu Fenglei | 2016-11-28 |
| Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer (NCT03299478) | University Hospital of North Norway | 2016-11-28 |
| A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (NCT02779751) | Eli Lilly and Company | 2016-11-14 |
| Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. (NCT03130881) | Beijing Pearl Biotechnology Limited Liability Company | 2016-11-08 |
| Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (NCT02835599) | AstraZeneca | 2016-11-01 |
| 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study (NCT02938546) | Shanghai Chest Hospital | 2016-11-01 |
| Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT02930954) | Caicun Zhou | 2016-11-01 |
| Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients (NCT02965391) | Peking University People's Hospital | 2016-11-01 |
| Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation (NCT02961270) | Chinese Academy of Medical Sciences | 2016-11-01 |
| Pembrolizumab-PET Imaging (NCT02760225) | University Medical Center Groningen | 2016-10-24 |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (NCT02789345) | Eli Lilly and Company | 2016-10-24 |
| Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC (NCT02768558) | RTOG Foundation, Inc. | 2016-10-17 |
| Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer (NCT02570815) | St. Joseph's Healthcare Hamilton | 2016-10-01 |
| Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients (NCT03372694) | Shanghai University of Traditional Chinese Medicine | 2016-10-01 |
| Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients (NCT03244605) | Shanghai University of Traditional Chinese Medicine | 2016-10-01 |
| Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients (NCT02579564) | Xinqiao Hospital of Chongqing | 2016-10-01 |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. (NCT03384511) | Shandong Cancer Hospital and Institute | 2016-09-30 |
| KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy) (NCT02777567) | AstraZeneca | 2016-09-29 |
| Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel (NCT02684461) | UNC Lineberger Comprehensive Cancer Center | 2016-09-13 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (NCT02841579) | MedSIR | 2016-09-02 |
| Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program (NCT02933346) | Intergroupe Francophone de Cancerologie Thoracique | 2016-09-01 |
| DE-CT in Lung Cancer Proton Therapy (NCT02844140) | Maastricht Radiation Oncology | 2016-09-01 |
| Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study (NCT02907606) | Peking University People's Hospital | 2016-09-01 |
| Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type (NCT02906150) | SciClone Pharmaceuticals | 2016-09-01 |
| Prognostic PET/CT Model in Non Small Cell Lung Cancer (NCT03199599) | Poitiers University Hospital | 2016-09-01 |
| Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (NCT02635061) | Celgene | 2016-08-25 |
| Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066) | HUYABIO International, LLC. | 2016-08-18 |
| Improving Pulmonary Function Following Radiation Therapy (NCT02843568) | University of Wisconsin, Madison | 2016-08-17 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780) | Eli Lilly and Company | 2016-08-10 |
| INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer (NCT02764086) | Cancer Trials Ireland | 2016-08-10 |
| Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy (NCT02910999) | Bristol-Myers Squibb | 2016-08-09 |
| Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) (NCT02835690) | Merck Sharp & Dohme LLC | 2016-08-04 |
| Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma (NCT03156868) | Spanish Lung Cancer Group | 2016-08-03 |
| Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC (NCT02771314) | Hellenic Oncology Research Group | 2016-08-02 |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study (NCT03850444) | Merck Sharp & Dohme LLC | 2016-08-01 |
| An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study (NCT02884479) | SciClone Pharmaceuticals International (Cayman) Development Limited | 2016-08-01 |
| Energy for Lymphocytes (NCT04879316) | Hôpital Cochin | 2016-08-01 |